EGFR Program for NSCLC

We are currently investigating the use of our pan-variant targeted therapies to help people with lung cancer.

Approximately 2.2 million new cases of lung cancer were diagnosed globally in 2020, with non-small cell lung cancer (NSCLC) being the most common form of the disease. Up to 50% of patients with NSCLC have tumors that are driven by activating mutations in the epidermal growth factor receptor (EGFR), and treatment with first-, second-, or third-generation EGFR kinase inhibitors is the standard of care for these patients.

The most common resistance mutation that develops from first- or later-line treatment with osimertinib, a third-generation inhibitor, is called C797S.

Our previous work discovering, developing, and launching cancer treatments serves as a springboard for the research and development of our advanced TKIs.

To address this problem of on-target resistance, we are developing a fourth-generation selective EGFR inhibitor, designed to inhibit the full range of single-, double-, and triple-mutant EGFR variants found in the tumors of patients with EGFR-mutant NSCLC that have developed resistance to osimertinib, including the C797S mutation.

We intend to nominate a development candidate from our EGFR inhibitor program in the third quarter of 2022, and thereafter initiate IND-enabling studies.